Edward Conner
Vermögen: 2 Mio $ am 30.06.2026
Vermögen: 2 Mio $ am 30.06.2026
Dr. Edward R.
Conner, MD, is a Chief Medical Officer at Jade Biosciences, Inc. Dr. Conner was previously employed as a Chief Medical Officer by Ardelyx, Inc., a Chief Medical Officer by Third Harmonic Bio, Inc., a Chief Medical Officer by Locanabio, Inc., an Independent Director by Imara, Inc., a Division Head-Gene Therapy Medical & Development by Astellas Gene Therapies, Inc., a Chief Medical Officer & Senior Vice President by Sangamo Therapeutics, Inc., a Vice President-Clinical Development by Ultragenyx Pharmaceutical, Inc., a Senior Medical Director by BioMarin Pharmaceutical, Inc., and a Medical Director by Genentech, Inc. He received his undergraduate degree from Duke University and a doctorate degree from The University of California, San Francisco.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARDELYX, INC. 0.12% | 01.08.2025 | 302’260 ( 0.12% ) | 2 Mio $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| JADE BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 22.04.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| ARDELYX, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.12.2025 |
| THIRD HARMONIC BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.07.2025 |
| IMARA | Direktor/Vorstandsmitglied | 24.02.2023 |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Develops and operates software platform for addressing a wide spectrum of human genetic diseases | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2022 |
| AUDENTES THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ardelyx, Inc.
Ardelyx, Inc. Pharmaceuticals: MajorHealth Technology Discovers and Develops therapeutic therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases | Health Technology |
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes gene therapy products for patients with serious rare diseases | Health Technology |
Imara, Inc.
Imara, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes novel therapeutics for patients with sickle cell disease | Health Technology |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Develops and operates software platform for addressing a wide spectrum of human genetic diseases | Technology Services |
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of allergic and immune diseases and disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen